EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PolyPeptide Group AG's enterprise value is CHF1,112.3 Mil.
PolyPeptide Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-21.5 Mil. Therefore, PolyPeptide Group AG's EV-to-EBITDA for today is -51.69.
The historical rank and industry rank for PolyPeptide Group AG's EV-to-EBITDA or its related term are showing as below:
XSWX:PPGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -53.21 Med: 21.84 Max: 66.91
Current: -51.69
During the past 6 years, the highest EV-to-EBITDA of PolyPeptide Group AG was 66.91. The lowest was -53.21. And the median was 21.84.
XSWX:PPGN's EV-to-EBITDA is ranked worse than 100% of 710
companies
in the Drug Manufacturers industry
Industry Median: 14.875
vs XSWX:PPGN: -51.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
PolyPeptide Group AG EV-to-EBITDA Historical Data
The historical data trend for PolyPeptide Group AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PolyPeptide Group AG's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's EV-to-EBITDA falls into.
PolyPeptide Group AG's current Enterprise Value is CHF1,112.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-21.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (XSWX:PPGN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PolyPeptide Group AG's PE Ratio for today is calculated as:
PolyPeptide Group AG's share price for today is CHF33.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-1.505.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of PolyPeptide Group AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PolyPeptide Group AG (XSWX:PPGN) Business Description
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:PPGN has been successfully added to your 